NCT05397171 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 16
- units
- Participants
- groups
- description
- Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- BG000
- title
- AZD8853 300 mg
- description
- Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- BG001
- title
- AZD8853 1000 mg
- description
- Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- BG002
- title
- AZD8853 3000 mg
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 13.2
- value
- 62.0
- group Id
- BG001
- spread
- 4.2
- value
- 62.8
- group Id
- BG002
- spread
- 7.4
- value
- 65.1
- group Id
- BG003
- spread
- 7.3
- value
- 63.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- comment
- Data are not reported due to concerns with participant's confidentiality.
- group Id
- BG000
- value
- NA
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG003
- value
- NA
- title
- Female
- measurements
- comment
- Data are not reported due to concerns with participant's confidentiality.
- group Id
- BG000
- value
- NA
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 4
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG003
- value
- NA
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 13
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- Not reported
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Safety set included all participants who received any amount of investigational product (IP).
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 16
- units
- Participants
- groups
- description
- Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- BG000
- title
- AZD8853 300 mg
- description
- Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- BG001
- title
- AZD8853 1000 mg
- description
- Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.
- id
- BG002
- title
- AZD8853 3000 mg
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 13.2
- value
- 62.0
- group Id
- BG001
- spread
- 4.2
- value
- 62.8
- group Id
- BG002
- spread
- 7.4
- value
- 65.1
- group Id
- BG003
- spread
- 7.3
- value
- 63.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- comment
- Data are not reported due to concerns with participant's confidentiality.
- group Id
- BG000
- value
- NA
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG003
- value
- NA
- title
- Female
- measurements
- comment
- Data are not reported due to concerns with participant's confidentiality.
- group Id
- BG000
- value
- NA
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 4
- comment
- Total not calculated because data are not available (NA) in one or more arms.
- group Id
- BG003
- value
- NA
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 13
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- Not reported
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Other
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- population Description
- Safety set included all participants who received any amount of investigational product (IP).
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle